PRT 001
Alternative Names: PRT-001Latest Information Update: 19 Feb 2026
At a glance
- Originator Protai
- Class Antineoplastics
- Mechanism of Action KAT6A protein degraders
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 19 Feb 2026 PRT 001 is available for licensing as of 19 Feb 2026. https://www.protai.bio/pipeline
- 10 Feb 2026 Preclinical trials in Cancer in USA (unspecified route), prior to February 2026
- 10 Feb 2026 Protai plans to file an IND in 2027 (Protai pipeline, February 2026)